Highlights I-Mab BOERSE MUENCHEN

Equities

0VY

US44975P1030

Market Closed - BOERSE MUENCHEN Other stock markets 15:43:52 2024-06-28 EDT			5-day change	1st Jan Change
1.57 ^EUR	-0.63%		-1.26%	-5.99%

06-06	I-Mab Appoints Phillip Dennis as Chief Medical Officer	CI
06-05	I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

I-Mab Collaborates With Bristol-Myers to Evaluate Givastomig in Combination Study for Gastric, Esophageal Cancers	06-05	MT
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers	06-05	CI
I-Mab Completes Business Divestiture in China	04-02	MT
I-mab Biopharma Co., Ltd. completed the acquisition of I-Mab Biopharma Co., Ltd. from I-Mab.	04-01	CI
I-Mab Reports Earnings Results for the Full Year Ended December 31, 2023	03-14	CI
Gilead Sciences pauses enrollment for cancer treatment in solid tumor trials	02-15	RE
Biotech firm I-Mab to divest China operations, shift focus to US	02-07	RE
Biotech firm I-Mab to divest China operations	02-07	RE
I-mab Biopharma Co., Ltd. agreed to acquire I-Mab Biopharma Co., Ltd. from I-Mab for $80 million.	02-06	CI
I-Mab and Hi-Bio Announces That the U.S. Food and Drug Administration Has Granted Breakthrough Therapy Designation for Felzartamab, an Investigational Cd38 Antibody, for the Treatment of Primary Memorbranous Nephropathy	11-02	CI
I-Mab Announces Phase 1 Data of Givastomig at Esmo 2023	23-10-16	CI
I-Mab and ABL Bio Announce Latest Updates of PD-L1 and 4-1Bb Bispecific Antibody Tj-L14b Abl503	23-10-10	CI
AbbVie Terminates $3 Billion Cancer Drug Deal With Biotech Firm I-Mab	23-09-25	MT
I-Mab Regains Global Rights to Lemzoparlimab	23-09-22	CI
Salesforce Earnings, Inflation Outlook Bolster Exchange-Traded Funds, Equity Futures Premarket Thursday	23-08-31	MT
I-Mab announces an Equity Buyback for $40 million worth of its shares.	23-08-17	CI
I-Mab Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-17	CI
I-Mab authorizes a Buyback Plan.	23-07-31	CI
I-Mab Announces Encouraging Phase 1b/2 Study Results of Patients with Advanced NSCLC	23-05-26	CI
Tranche Update on I-Mab's Equity Buyback Plan announced on August 30, 2022.	23-05-01	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights I-Mab BOERSE MUENCHEN

Equities

0VY

US44975P1030

Highlights

Filters